US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Eikon Therapeutics

8.94

-0.2700-2.93%

Post-market: 8.940.00000.00%19:30 EDT

Volume:1.01M

Turnover:9.08M

Market Cap:482.62M

PE:-1.50

High:9.56

Open:9.28

Low:8.79

Close:9.21

52wk High:17.40

52wk Low:7.90

Shares:53.98M

Float Shares:17.65M

Volume Ratio:2.02

T/O Rate:5.72%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.9500

EPS(LYR):-115.2900

ROE:-125.02%

ROA:-36.19%

PB:1.03

PE(LYR):-0.08

Loading ...

Overview Company News Filings

Eikon Therapeutics Announces Recent Board Director Resignations

Eikon Therapeutics Directors Leon Chen, Joshua Wolfe Resign from Board

Eikon Therapeutics Doses First Patient in TeLuRide-008 Phase 2/3 NSCLC Trial of Eik1001 Combo

Eikon Therapeutics Announces First Patient Dosed in Teluride-008, a Registrational Phase 2/3 Trial of Eik1001 in Non-Small Cell Lung Cancer

THOMSON REUTERS

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

Eikon Therapeutics Flags Availability of ESMO 2026 Abstracts Press Release

EIKN’s TeLuRide-008 Trial: A New Lung Cancer Combo Investors Should Watch

Eikon Therapeutics to be added to Russell 3000 Index

Eikon Therapeutics to Join the Russell 3000® Index

Eikon Therapeutics director Francisco Ma. Fatima files initial beneficial ownership statement

Eikon Therapeutics appoints Ma. Fatima D. Francisco to board

Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to Its Board of Directors

THOMSON REUTERS

Press Release: Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors

Eikon Therapeutics price target lowered to $32 from $34 at BofA

Eikon Therapeutics, Inc. (EIKN) Receives a Buy from Bank of America Securities

Analysts Offer Insights on NA Companies: Eikon Therapeutics, Inc. (EIKN) and Cracker Barrel (CBRL)

Eikon Therapeutics presents data on lead programs at ASCO 2026

Eikon reports 63.1% response rate in Phase 2 EIK1001 first-line stage 4 NSCLC trial

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Eikon presents Phase 2 TeLuRide-005 EIK1001 data in stage 4 NSCLC at ASCO 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/EIKN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EIKN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":8.94,"timestamp":1789156800000,"preClose":9.21,"halted":0,"volume":1010238,"hourTrading":{"tag":"盘后","latestPrice":8.94,"preClose":8.94,"latestTime":"19:30 EDT","volume":15,"amount":134.16,"timestamp":1789169408186,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.029315960912052262,"floatShares":17648000,"shares":53984300,"eps":-5.95,"marketStatus":"Market Closed","change":-0.27,"latestTime":"09-11 16:00:00 EDT","open":9.28,"high":9.56,"low":8.79,"amount":9076866.696321,"amplitude":0.083605,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-5.95,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":9.21,"preHourTrading":{"tag":"盘前","latestPrice":9.1759,"preClose":9.21,"latestTime":"07:03 EDT","volume":251,"amount":2303.355214,"timestamp":1789124637568,"change":-0.0341,"changeRate":-0.003702,"amplitude":0.022161},"postHourTrading":{"tag":"盘后","latestPrice":8.94,"preClose":8.94,"latestTime":"19:30 EDT","volume":15,"amount":134.16,"timestamp":1789169408186,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.016145320174848},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","floatShares":17648000,"roa":"-36.19%","roe":"-125.02%","lyrEps":-115.29,"volumeRatio":2.016145320174848,"shares":53984300,"dividePrice":0,"high":9.56,"amplitude":0.083605,"preClose":9.21,"low":8.79,"week52Low":7.9,"pbRate":"1.03","week52High":17.4,"institutionHeld":0,"latestPrice":8.94,"eps":-5.95,"divideRate":0,"volume":1010238,"delay":0,"ttmEps":-5.95,"open":9.28,"prevYearClose":18,"prevWeekClose":10.86,"prevMonthClose":10.46,"prevQuarterClose":13.05,"fiveDayClose":10.96,"twentyDayClose":10.33,"sixtyDayClose":9.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EIKN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"EIKN","fiscalQuarterEnding":"2026/06","expectedEps":-1.61,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.63},{"market":"US","date":"2026-05-11","symbol":"EIKN","fiscalQuarterEnding":"2026/03","expectedEps":-1.47,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-2.46}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EIKN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EIKN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0,"sell":0,"strongSell":0.1667,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1774929600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EIKN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EIKN","date":"2026-09-11","current":-1.502521,"percent":0.778523,"low":-3.139466,"twenty":-2.084271,"median":-1.760899,"eighty":-1.536491,"high":-1.335246,"avg":-1.859141,"sd":0.375632,"marketCap":498859926},"quantilePoints":[{"date":"2026-02-06","current":-2.616222,"twenty":-3.034817,"median":-2.877844,"eighty":-2.720871,"marketCap":809765055},{"date":"2026-02-13","current":-2.586571,"twenty":-2.610292,"median":-2.537735,"eighty":-2.527619,"marketCap":800587717},{"date":"2026-02-20","current":-2.703429,"twenty":-2.7418,"median":-2.616222,"eighty":-2.529014,"marketCap":836757223},{"date":"2026-02-27","current":-2.379017,"twenty":-2.703429,"median":-2.596164,"eighty":-2.52727,"marketCap":736346356},{"date":"2026-03-06","current":-2.535991,"twenty":-2.644128,"median":-2.595292,"eighty":-2.523782,"marketCap":784932259},{"date":"2026-03-13","current":-2.054606,"twenty":-2.624942,"median":-2.562153,"eighty":-2.406924,"marketCap":635935489},{"date":"2026-03-20","current":-1.915074,"twenty":-2.616222,"median":-2.529014,"eighty":-2.298787,"marketCap":592748020},{"date":"2026-03-27","current":-1.836588,"twenty":-2.600524,"median":-2.515933,"eighty":-2.054606,"marketCap":568455068},{"date":"2026-04-02","current":-1.678228,"twenty":-2.599129,"median":-2.426109,"eighty":-1.985189,"marketCap":544162116},{"date":"2026-04-10","current":-1.504368,"twenty":-2.597385,"median":-2.379017,"eighty":-1.821565,"marketCap":487788380},{"date":"2026-04-17","current":-1.876704,"twenty":-2.595641,"median":-2.269137,"eighty":-1.751381,"marketCap":608517358},{"date":"2026-04-24","current":-1.786542,"twenty":-2.595292,"median":-2.061583,"eighty":-1.769507,"marketCap":579282538},{"date":"2026-05-01","current":-1.605383,"twenty":-2.588315,"median":-2.045013,"eighty":-1.651966,"marketCap":520542206},{"date":"2026-05-08","current":-1.531083,"twenty":-2.547502,"median":-1.986901,"eighty":-1.641614,"marketCap":496450549},{"date":"2026-05-15","current":-2.105086,"twenty":-2.53634,"median":-1.963159,"eighty":-1.651966,"marketCap":713546154},{"date":"2026-05-22","current":-1.782455,"twenty":-2.530409,"median":-1.936811,"eighty":-1.659647,"marketCap":604186273},{"date":"2026-05-29","current":-1.645097,"twenty":-2.527968,"median":-1.929027,"eighty":-1.650964,"marketCap":557627116},{"date":"2026-06-05","current":-1.562046,"twenty":-2.525177,"median":-1.895889,"eighty":-1.633553,"marketCap":529475781},{"date":"2026-06-12","current":-1.360801,"twenty":-2.514363,"median":-1.841551,"eighty":-1.597703,"marketCap":461261110},{"date":"2026-06-18","current":-1.55406,"twenty":-2.482968,"median":-1.809917,"eighty":-1.567693,"marketCap":526768850},{"date":"2026-06-26","current":-1.573226,"twenty":-2.429947,"median":-1.776985,"eighty":-1.53713,"marketCap":533265485},{"date":"2026-07-02","current":-1.95655,"twenty":-2.406226,"median":-1.79823,"eighty":-1.541282,"marketCap":663198193},{"date":"2026-07-10","current":-1.79204,"twenty":-2.398552,"median":-1.809917,"eighty":-1.555657,"marketCap":607435406},{"date":"2026-07-17","current":-1.589198,"twenty":-2.377273,"median":-1.784498,"eighty":-1.563963,"marketCap":538679348},{"date":"2026-07-24","current":-1.536491,"twenty":-2.355995,"median":-1.761474,"eighty":-1.543838,"marketCap":520813601},{"date":"2026-07-31","current":-1.536491,"twenty":-2.298787,"median":-1.731347,"eighty":-1.536491,"marketCap":520813601},{"date":"2026-08-07","current":-1.471006,"twenty":-2.239486,"median":-1.715581,"eighty":-1.534894,"marketCap":498616763},{"date":"2026-08-14","current":-1.736786,"twenty":-2.116266,"median":-1.712181,"eighty":-1.534894,"marketCap":559524759},{"date":"2026-08-21","current":-1.807401,"twenty":-2.105086,"median":-1.719889,"eighty":-1.534894,"marketCap":582274072},{"date":"2026-08-28","current":-1.936861,"twenty":-2.105086,"median":-1.736786,"eighty":-1.536491,"marketCap":623981145},{"date":"2026-09-04","current":-1.842708,"twenty":-2.084325,"median":-1.759483,"eighty":-1.536491,"marketCap":593648728},{"date":"2026-09-11","current":-1.54848,"twenty":-2.084271,"median":-1.760899,"eighty":-1.536491,"marketCap":498859926}],"updateTime":1789206291005},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EIKN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656300172","title":"Eikon Therapeutics Announces Recent Board Director Resignations","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300172","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300172?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:32","pubTimestamp":1785796348,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics, Inc. ( ($EIKN) ) has provided an announcement. On July 31, 2026, Eikon Therapeutics, Inc., a biotechnology company focused on d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-announces-recent-board-director-resignations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eikon-therapeutics-announces-recent-board-director-resignations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DARP","BK4585","SYNB","XT","EIKN","IBB","AGNG","IEIH","BBP","RSPH","FWD","LNGR","BK4588","FHLC","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656302677","title":"Eikon Therapeutics Directors Leon Chen, Joshua Wolfe Resign from Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2656302677","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656302677?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:51","pubTimestamp":1785790274,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics directors Leon Chen, Joshua Wolfe resign from boardEikon Therapeutics reported board resignations by Leon Chen and Joshua Wolfe, effective July 31, 2026.Both departures were not tie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL1YqtH7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654701268","title":"Eikon Therapeutics Doses First Patient in TeLuRide-008 Phase 2/3 NSCLC Trial of Eik1001 Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2654701268","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654701268?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:31","pubTimestamp":1785151900,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics doses first patient in TeLuRide-008 Phase 2/3 NSCLC trial of EIK1001 comboEikon Therapeutics dosed the first patient in TeLuRide-008, a registrational Phase 2/3 trial of EIK1001 in ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL8slyDj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","LU2210149790.SGD","LU0314104364.USD","IE00B64PRP62.GBP","BCDF","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4112","IE00BN0W2T93.GBP","SG9999014039.USD","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","BK4585","BK4139","EIKN","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4588","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654012511","title":"Eikon Therapeutics Announces First Patient Dosed in Teluride-008, a Registrational Phase 2/3 Trial of Eik1001 in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2654012511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654012511?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:30","pubTimestamp":1785151800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA1SLY2C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654012763","title":"Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2654012763","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654012763?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:30","pubTimestamp":1785151800,"startTime":"0","endTime":"0","summary":"MILLBRAE, Calif., July  27, 2026  (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/27/3333400/0/en/Eikon-Therapeutics-Announces-First-Patient-Dosed-in-TeLuRide-008-a-Registrational-Phase-2-3-Trial-of-EIK1001-in-Non-Small-Cell-Lung-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","L","EIKN","LU0053666078.USD","BK4588","LU0210528500.USD","BK4585","BK4139","LU2487616109.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652831213","title":"Eikon Therapeutics Flags Availability of ESMO 2026 Abstracts Press Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2652831213","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652831213?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:01","pubTimestamp":1784548890,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics flags availability of ESMO 2026 abstracts press releaseEikon posted a press release on seven abstracts accepted for presentation at the 2026 ESMO Congress in Madrid.Updates span EIK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDLb5QGSn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","NDAQ","IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","BK4112","IE00BN0W2V16.EUR","BCDF","LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","SG9999014039.USD","IE00B3QW5Z07.USD","EIKN","IE00BGHQF748.EUR","BK4139","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651607467","title":"EIKN’s TeLuRide-008 Trial: A New Lung Cancer Combo Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2651607467","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651607467?lang=en_us&edition=fundamental","pubTime":"2026-07-16 00:31","pubTimestamp":1784133088,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics, Inc. ($EIKN) announced an update on their ongoing clinical study. The TeLuRide-008 study from Eikon Therapeutics, Inc. tests EI...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eikns-teluride-008-trial-a-new-lung-cancer-combo-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eikns-teluride-008-trial-a-new-lung-cancer-combo-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","BK4211","EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646861583","title":"Eikon Therapeutics to be added to Russell 3000 Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2646861583","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646861583?lang=en_us&edition=fundamental","pubTime":"2026-06-26 04:25","pubTimestamp":1782419109,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics (EIKN) announced that it will be added to the broad-market Russell 3000 Index following the annual reconstitution, effective aft...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-to-be-added-to-russell-3000-index-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-to-be-added-to-russell-3000-index-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646857973","title":"Eikon Therapeutics to Join the Russell 3000® Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2646857973","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646857973?lang=en_us&edition=fundamental","pubTime":"2026-06-26 04:15","pubTimestamp":1782418500,"startTime":"0","endTime":"0","summary":"Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment communityMILLBRAE, Calif., June  25, 2026  (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317939/0/en/Eikon-Therapeutics-to-Join-the-Russell-3000-Index.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643785032","title":"Eikon Therapeutics director Francisco Ma. Fatima files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2643785032","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643785032?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:31","pubTimestamp":1781555495,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics director Francisco Ma. Fatima disclosed a stock option for 85,937 common shares at an $8.96 exercise price.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL6Mmpdf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642796475","title":"Eikon Therapeutics appoints Ma. Fatima D. Francisco to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2642796475","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642796475?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:16","pubTimestamp":1781122619,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics appointed Ma. Fatima D. Francisco to its board as a Class I director, effective June 15, 2026.Francisco will serve through the 2027 annual stockholders meeting, subject to earlier resignation, removal, or other departure.She will initially join the board’s Compensation Committee.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL4vjsDQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641481630","title":"Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641481630","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641481630?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:00","pubTimestamp":1780920003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUA3P97XK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641248154","title":"Press Release: Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641248154","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641248154?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:00","pubTimestamp":1780920000,"startTime":"0","endTime":"0","summary":"MILLBRAE, Calif., June 08, 2026  -- Eikon Therapeutics, Inc.  , a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ma. Fatima  D. Francisco as an independent director to Eikon's Board of Directors, effective June 15, 2026. Ms. Francisco will also serve on the Compensation Committee of the Board.\"Fama brings a remarkable record of leadership, innovation and talent development from one of the world's most successful global enterprises,\" said Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer of Eikon. \"Her perspectives on commercial planning, operational execution and cultivating high-performing teams will be invaluable as Eikon continues to build a global, fully integrated organization developing important, innovative medicines to address serious unmet medical needs. We are delighted to welcome Fama to the Board.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640918876","title":"Eikon Therapeutics price target lowered to $32 from $34 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2640918876","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640918876?lang=en_us&edition=fundamental","pubTime":"2026-06-03 23:20","pubTimestamp":1780500040,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Eikon Therapeutics (EIKN) to $32 from $34 and keeps a Buy rating on the shares. Eikon’s Q1 report was “rela...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-price-target-lowered-to-32-from-34-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-price-target-lowered-to-32-from-34-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640909200","title":"Eikon Therapeutics, Inc. (EIKN) Receives a Buy from Bank of America Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2640909200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640909200?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:39","pubTimestamp":1780486777,"startTime":"0","endTime":"0","summary":"In a report released today, Jason Zemansky from Bank of America Securities reiterated a Buy rating on Eikon Therapeutics, Inc., with a price target...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/eikon-therapeutics-inc-eikn-receives-a-buy-from-bank-of-america-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/eikon-therapeutics-inc-eikn-receives-a-buy-from-bank-of-america-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3581.USD","BAC","BK4585","IE00BLSP4239.USD","BK4588","LU0128525689.USD","LU0106831901.USD","LU1880398554.USD","BK4553","LU1496350502.SGD","LU0314106906.USD","LU0256863811.USD","LU1894683348.USD","LU1267930227.SGD","IE00BLSP4452.SGD","LU1668664300.SGD","LU0256863902.USD","LU1506573853.SGD","EIKN","LU0098860793.USD","LU0211331839.USD","LU1883839398.USD","LU0234570918.USD","BK4139","LU0477156797.USD","LU0234572021.USD","BK4207","IE00B19Z3B42.SGD","LU0310800965.SGD","IE00BBT3K403.USD","LU0648001328.SGD","LU0149725797.USD","LU0321505868.SGD","LU0640476718.USD","BK4559","LU0130517989.USD","BK4582","LU1496350171.SGD","LU1791807156.HKD","LU1366192091.USD","LU0648000940.SGD","IE00BKVL7J92.USD","PGF","IE00B1BXHZ80.USD","LU0170899867.USD","LU1280957306.USD","BK4581","IE00B7SZLL34.SGD","LU0321505439.SGD","LU1201861249.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640098490","title":"Analysts Offer Insights on NA Companies: Eikon Therapeutics, Inc. (EIKN) and Cracker Barrel (CBRL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640098490","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640098490?lang=en_us&edition=fundamental","pubTime":"2026-06-01 09:10","pubTimestamp":1780276234,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the NA sector with new ratings on Eikon Therapeutics, Inc. (EIKN) and Cracker Barrel (CBRL). Eikon Therapeu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-eikon-therapeutics-inc-eikn-and-cracker-barrel-cbrl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-eikon-therapeutics-inc-eikn-and-cracker-barrel-cbrl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN","BK4209","BK4139","BK4141","NA","CBRL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640698662","title":"Eikon Therapeutics presents data on lead programs at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640698662","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640698662?lang=en_us&edition=fundamental","pubTime":"2026-06-01 05:10","pubTimestamp":1780261805,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics (EIKN) announced presentations on several of its lead programs at the 2026 American Society of Clinical Oncology, ASCO, Annual M...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-presents-data-on-lead-programs-at-asco-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eikon-therapeutics-presents-data-on-lead-programs-at-asco-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639601032","title":"Eikon reports 63.1% response rate in Phase 2 EIK1001 first-line stage 4 NSCLC trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2639601032","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639601032?lang=en_us&edition=fundamental","pubTime":"2026-05-31 02:32","pubTimestamp":1780165937,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics outlined new clinical updates for EIK1001 in first-line stage 4 NSCLC, with results already presented at the 2026 ASCO meeting.The study strengthened the development case, showing broad tumor shrinkage signals and sustained disease control, with tolerability consistent with standard treatment.It also released updated Phase 1/2 findings for PARP1 inhibitor EIK1003, with results already presented at ASCO 2026.EIK1003 showed continued single-agent activity, with early combination activity alongside weekly paclitaxel in heavily pretreated patients, without unexpected safety signals.Upcoming readouts include studies advancing EIK1001 into later-stage trials, with additional ASCO abstracts signaling expansion into melanoma and confirmatory NSCLC programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260530:nNDL2v0g74:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639048566","title":"Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2639048566","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639048566?lang=en_us&edition=fundamental","pubTime":"2026-05-31 02:30","pubTimestamp":1780165800,"startTime":"0","endTime":"0","summary":"TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease cont","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/30/3303899/0/en/Eikon-Therapeutics-Presents-Data-on-Clinical-Stage-Programs-at-the-2026-Annual-Meeting-of-the-American-Society-of-Clinical-Oncology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2487616109.SGD","IE0031619046.USD","AFG","BK4187","BK4585","BK4117","CRS","LU2065731478.USD","ORR","BK4139","BK4107","LU0963586101.USD","BK4006","EIKN","IE00B66KJ199.SGD","IE00B19Z4B17.USD","LU0053666078.USD","BK4588","L","IE00B7SZL793.SGD","SSI","LU0210528500.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637368971","title":"Eikon presents Phase 2 TeLuRide-005 EIK1001 data in stage 4 NSCLC at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637368971","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637368971?lang=en_us&edition=fundamental","pubTime":"2026-05-22 07:19","pubTimestamp":1779405560,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics on May 21, 2026 flagged six oncology abstracts that will be presented at the 2026 ASCO annual meeting starting May 29, 2026.Planned presentations highlight ongoing mid- to late-stage studies of EIK1001 in first-line stage 4 non-small cell lung cancer, including combinations with standard regimens, with an update focused on efficacy, safety, and immune-response profiling.Additional abstracts will outline early clinical progress for EIK1003 in advanced solid tumors, including combination use with paclitaxel, alongside updated monotherapy findings.EIK1005 updates will cover first-in-human safety and pharmacokinetics in healthy participants, with a separate trial design for use alone or with pembrolizumab in advanced solid tumors such as MSI-H or dMMR cancers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL2RsHWf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":54,"code":"91000000","status":"200"}]}}